偉志控股(01305.HK)擬590萬美元收購半導體設備
格隆匯11月11日丨偉志控股(01305.HK)發佈公告,於2020年11月11日,公司間接全資持有的附屬公司偉志惠州與賣方Victoria Ultra Business Co., Ltd.訂立該協議,據此,偉志惠州有條件同意收購該設備,現金代價為約590萬美元。建議收購事項如經落實,集團可開展半導體內存芯片測試和封裝業務。
設備主要包括上片機;焊線機器;記憶卡處理相關設備;電射切割和刻字機器;及其他內存芯片封裝和測試設備,主要用來支援及令集團有能力推行半導體內存芯片測試及封裝業務。
董事認為,建議收購事項如能落實,將令集團有能力推出與SLC及MLC芯片相關的測試及封裝業務,並拓闊集團的收入來源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.